4,781 Shares in Zymeworks Inc. (NYSE:ZYME) Acquired by New York State Teachers Retirement System

New York State Teachers Retirement System acquired a new position in Zymeworks Inc. (NYSE:ZYME) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,781 shares of the company’s stock, valued at approximately $50,000.

Several other institutional investors and hedge funds also recently bought and sold shares of ZYME. BlackRock Inc. boosted its holdings in Zymeworks by 371.4% in the 2nd quarter. BlackRock Inc. now owns 3,542,678 shares of the company’s stock worth $30,609,000 after buying an additional 2,791,105 shares during the period. State Street Corp boosted its holdings in Zymeworks by 492.3% in the 2nd quarter. State Street Corp now owns 906,325 shares of the company’s stock valued at $7,831,000 after purchasing an additional 753,308 shares during the period. Sessa Capital IM L.P. bought a new position in Zymeworks in the 4th quarter valued at $5,823,000. Acadian Asset Management LLC boosted its holdings in Zymeworks by 742.4% in the 3rd quarter. Acadian Asset Management LLC now owns 825,988 shares of the company’s stock valued at $5,233,000 after purchasing an additional 727,934 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Zymeworks by 126.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,179,893 shares of the company’s stock valued at $6,253,000 after purchasing an additional 659,457 shares during the period. 92.89% of the stock is owned by institutional investors.

Zymeworks Price Performance

Shares of NYSE:ZYME opened at $8.85 on Friday. The firm has a fifty day moving average price of $10.76 and a two-hundred day moving average price of $9.54. Zymeworks Inc. has a one year low of $6.01 and a one year high of $13.14. The company has a market cap of $624.54 million, a price-to-earnings ratio of -5.09 and a beta of 1.14.

Zymeworks (NYSE:ZYME) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.19. Zymeworks had a negative net margin of 156.12% and a negative return on equity of 26.20%. The firm had revenue of $16.93 million during the quarter, compared to the consensus estimate of $18.32 million. Equities research analysts expect that Zymeworks Inc. will post -1.04 EPS for the current fiscal year.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.